“Canada’s drug access debate has two ends: patients are caught in the middle,” Op-Ed by Arthritis Consumer Experts (ACE)

ACE submitted an Op-Ed to the Globe and Mail, Canada’s national newspaper of record in response to an article focused on whether Canada’s drug pricing policies discourage pharmaceutical companies from launching innovative therapies. In its Op-Ed, ACE counters that even after breakthrough medicines are approved and widely used, some remain priced at monopoly pricing levels for years longer due to the strategic use of patent protections to postpone competition from more affordable alternatives.